Targeting Filamin A Reduces Macrophage Activity and Atherosclerosis von Bandaru, Sashidar, Ala, Chandu, Salimi, Reza, Akula, Murali K, Ekstrand, Matias, Devarakonda, Sravani, Karlsson, Joakim, Van den Eynden, Jimmy, Bergström, Göran, Larsson, Erik, Levin, Max, Borén, Jan, Bergo, Martin O, Akyürek, Levent M

Volltext

11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma von Siaw, Joachim Tetteh, Javanmardi, Niloufar, Van den Eynden, Jimmy, Lind, Dan Emil, Fransson, Susanne, Martinez-Monleon, Angela, Djos, Anna, Sjöberg, Rose-Marie, Östensson, Malin, Carén, Helena, Trøen, Gunhild, Beiske, Klaus, Berbegall, Ana P., Noguera, Rosa, Lai, Wei-Yun, Kogner, Per, Palmer, Ruth H., Hallberg, Bengt, Martinsson, Tommy

Volltext

Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC von Bokhari, A.A., Lai, W-Y., Le, A.T., Gabre, J.L., Chuang, T-P., Fransson, S., Bergman, B., Djos, A., Chen, N., Martinsson, T., Van den Eynden, J., Doebele, R.C., Palmer, R.H., Hallberg, B., Umapathy, G.

Volltext

Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways von Umapathy, G, Van den Eynden, J, Cervantes-Madrid, D, Szydzik, J, Guan, J, Palmer, R H, Hallberg, B

Volltext

An antisense RNA capable of modulating the expression of the tumor suppressor microRNA-34a von Serviss, Jason T., Andrews, Nathanael, Van den Eynden, Jimmy, Richter, Felix Clemens, Houtman, Miranda, Vesterlund, Mattias, Schwarzmueller, Laura, Johnsson, Per, Larsson, Erik, Grandér †, Dan, Pokrovskaja Tamm, Katja

Volltext

ATR inhibition enables complete tumour regression in ALK-driven NB mouse models von Szydzik, Joanna, Lind, Dan E., Arefin, Badrul, Kurhe, Yeshwant, Umapathy, Ganesh, Siaw, Joachim Tetteh, Claeys, Arne, Gabre, Jonatan L., Van den Eynden, Jimmy, Hallberg, Bengt, Palmer, Ruth H.

Volltext

PO-121 ALK dependant phosphoproteome and gene expression profiling of neuroblastoma cells von Szydzik, J, Van den Eynden, J, Umapathy, G, Ashouri, A, Cervantes-Madrid, D, Palmer, R, Hallberg, B, Lekholm, E Larsson, Ruuth, K

Volltext

A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues von Luijts, Tom, Elliott, Kerryn, Siaw, Joachim Tetteh, Van de Velde, Joris, Beyls, Elien, Claeys, Arne, Lammens, Tim, Larsson, Erik, Willaert, Wouter, Vral, Anne, Van den Eynden, Jimmy

Volltext

Pharmacologic RNA splicing modulation: a novel mechanism to enhance neoantigen-directed anti-tumor immunity and immunotherapy response von Elliott, Kerryn, Nilsson, Jonas, Van den Eynden, Jimmy

Volltext

EP16.03-012 Novel Human-derived EML4-ALK Fusion cell lines identify ribonucleotide reductase RRM2 as a Target of Activated ALK in NSCLC von Umapathy, G., Bokhari, A., Lai, W.-Y., Le, A., Chuang, T.-P., Fransson, S., Martinsson, T., Van den Eynden, J., Doebele, R., Palmer, R.H., Hallberg, B.

Volltext

Loss of RET Promotes Mesenchymal Identity in Neuroblastoma Cells von Siaw, Joachim T., Gabre, Jonatan L., Uckun, Ezgi, Vigny, Marc, Zhang, Wancun, Van den Eynden, Jimmy, Hallberg, Bengt, Palmer, Ruth H., Guan, Jikui

Volltext

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib von Guan, Jikui, Fransson, Susanne, Siaw, Joachim Tetteh, Treis, Diana, Van den Eynden, Jimmy, Chand, Damini, Umapathy, Ganesh, Ruuth, Kristina, Svenberg, Petter, Wessman, Sandra, Shamikh, Alia, Jacobsson, Hans, Gordon, Lena, Stenman, Jakob, Svensson, Pär-Johan, Hansson, Magnus, Larsson, Erik, Martinsson, Tommy, Palmer, Ruth H, Kogner, Per, Hallberg, Bengt

Volltext

13PPhosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways von Umapathy, G, Van den Eynden, J, Cervantes-Madrid, D, Szydzik, J, Guan, J, Palmer, R H, Hallberg, B

Volltext

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma o the ALK inhibitor ceritinib von Guan, Jikui, Fransson, Susanne, Siaw, Joachim Tetteh, Treis, Diana, Van den Eynden, Jimmy, Chand, Damini, Umapathy, Ganesh, Ruuth, Kristina, Svenberg, Petter, Wessman, Sandra, Shamikh, Alia, Jacobsson, Hans, Gordon, Lena, Stenman, Jakob, Svensson, Pär-Johan, Hansson, Magnus, Larsson, Erik, Martinsson, Tommy, Palmer, Ruth H., Kogner, Per, Hallberg, Bengt

Volltext

Oxidant-Controlled Stereoselectivity in the Pd-Catalyzed Allylic Oxidation of cis-Vinylsilanes von Check, Christopher T, Henderson, William H, Wray, Brenda C, Vanden Eynden, Matthew J, Stambuli, James P

Volltext

Evaluation of anatomy based reconstruction for partial volume correction in brain FDG-PET von Baete, Kristof, Nuyts, Johan, Laere, Koen Van, Van Paesschen, Wim, Ceyssens, Sarah, De Ceuninck, Liesbet, Gheysens, Olivier, Kelles, Annemarie, Van den Eynden, Jimmy, Suetens, Paul, Dupont, Patrick

Volltext

BelPHG-21: a pilot study on genetic variability in the Belgian population von Descamps, T, Delporte, E, Vermeesch, J, Goetghebeur, E, Clement, L, Tafforeau, J, Demarest, S, Van Oyen, H, Van den Bulcke, M, Van den Eynden, J

Volltext

Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1 von Van Laere, K, De Ceuninck, L, Dom, R, Van den Eynden, J, Vanbilloen, H, Cleynhens, J, Dupont, P, Bormans, G, Verbruggen, A, Mortelmans, L

Volltext

Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-²-CIT versus 99mTc-TRODAT-1 von K. Van Laere, De Ceuninck, L, Dom, R, Van den Eynden, J, Vanbilloen, H, Cleynhens, J, Dupont, P, Bormans, G, Verbruggen, A, Mortelmans, L

Volltext

Simultaneous discovery of cancer subtypes and subtype features by molecular data integration von Le, T. van, Leeuwen, M. van, Fierro, A.C., Maeyer, D. de, Van den Eynden, J., Verbeke, .L., De Raedt, L., Marchal, K., Nijssen, S.G.R.

Volltext bestellen